La cadena de opciones muestra datos clave de las opciones de acciones de Veeva Systems a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Veeva Systems..

Veeva Systems (NYSE:VEEV) Bolsa, Cadena de Opciones

Veeva Systems

Veeva Sys

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

Veeva Systems Inc

VEEVA SYSTEMS ORD

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $240 to $260.

News

Price Target

Analyst Ratings

VEEV

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $260

RBC Capital analyst Rishi Jaluria maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $250 to $275.

RBC Capital Maintains Outperform on Veeva Systems, Raises Price Target to $275

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) price target from $110 to $140. Piper Sandler analyst Matt Farrell reiterated an Overweight rating. Trade Desk shares closed at $132.53 on Wednesday. See how other analysts view this stock.</li>
<li>Scotiabank raised the price target for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from $85 to $87. Scotiabank analyst Patrick Colville maintained a Sector Perform rating. Cloudflare shares closed at $95.66 on Thursday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo raised the price target for Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from $19 to $41. Wells Fargo analyst Stan Berenshteyn upgraded the stock from Underweight to Equal-Weight. Doximity shares closed at $43.42 on Thursday. <a href="https://www.benzinga.com/quote/DOCS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) price target from $39 to $37. Baird analyst Colin Sebastian maintained a Neutral rating. Yelp shares settled at $36.37 on Thursday. <a href="https://www.benzinga.com/quote/YELP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) price target from $275 to $305. Telsey Advisory Group analyst Joseph Feldman upgraded the stock from Market Perform to Outperform. Lowe&#8217;s shares closed at $266.30 on Thursday. <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) price target from $80 to $88. Baird analyst Shrenik Kothari maintained an Outperform rating. Fortinet shares closed at $83.68 on Thursday. <a href="https://www.benzinga.com/quote/FTNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised the price target for Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) from $28 to $40. Citigroup analyst Steven Zaccone upgraded the stock from Neutral to Buy. Chewy shares settled at $30.79 on Thursday. <a href="https://www.benzinga.com/quote/CHWY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) price target from $230 to $280. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Veeva shares closed at $223.39 on Thursday. <a href="https://www.benzinga.com/quote/VEEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised the price target for Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from $18 to $24. Stifel analyst Mathew Blackman upgraded the stock from Hold to Buy. Orthofix Medical shares closed at $18.22 on Thursday. <a href="https://www.benzinga.com/quote/OFUX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Under Armour, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) price target from $8 to $10. Baird analyst Jonathan Komp maintained a Neutral rating. Under Armour shares closed at $11.13 on Thursday. <a href="https://www.benzinga.com/quote/UAA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CHWY

DOCS

FTNT

OFIX

YELP

Lowe's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Friday

WIIM

Veeva Systems shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $230 to $280.

Needham analyst Ryan MacDonald reiterates Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and maintains $260 price target.

Reiteration

Needham Reiterates Buy on Veeva Systems, Maintains $260 Price Target

Piper Sandler analyst Brent Bracelin maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $230 to $280.

Piper Sandler Maintains Overweight on Veeva Systems, Raises Price Target to $280

Veeva Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) short percent of float has risen 15.38% since its last report. The company recently reported that it has 2.21 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Veeva Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730135718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Veeva Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Veeva Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Veeva Systems's peer group average for short interest as a percentage of float is 6.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Veeva Systems's Recent Short Interest

During the last three months, 15 analysts shared their evaluations of Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Veeva Systems and provided 12-month price targets. The average target is $239.27, accompanied by a high estimate of $286.00 and a low estimate of $192.00. Witnessing a positive shift, the current average has risen by 6.14% from the previous average price target of $225.43.
<img src="https://www.benzinga.com/files/images/story/2024/1730116840_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Veeva Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$245.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Andrew DeGasperi</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Outperform</td>
<td>$286.00</td>
<td>-</td>
</tr>
<tr>
<td>Jack Wallace</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$249.00</td>
<td>$233.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$208.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$207.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$192.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$281.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veeva Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Veeva Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Veeva Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veeva Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VEEV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veeva Systems analyst ratings.</a>
<h2>Get to Know Veeva Systems Better</h2>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>Understanding the Numbers: Veeva Systems's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Veeva Systems's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of 14.56%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Veeva Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Veeva Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Veeva Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.73% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Veeva Systems's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Have This To Say About Veeva Systems

Baird analyst Joe Vruwink maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and lowers the price target from $251 to $245.

Baird Maintains Outperform on Veeva Systems, Lowers Price Target to $245

Walgreens And Veeva Systems Enter Long-Term Partnership To Enhance Patient Outcomes; Walgreens Gains Access To Veeva Data Cloud And Clinical Platform To Better Serve Life Sciences Industry

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.11% on an annualized basis producing an average annual return of 22.42%. Currently, Veeva Systems has a market capitalization of $35.48 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $7,593.22 today based on a price of $219.11 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729697410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Veeva Systems 10 Years Ago Would Be Worth Today

Veeva Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) short percent of float has risen 11.63% since its last report. The company recently reported that it has 2.12 million shares sold short, which is 1.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Veeva Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728491418_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Veeva Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Veeva Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Veeva Systems's peer group average for short interest as a percentage of float is 6.36%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(VEEV) - Analyzing Veeva Systems's Short Interest

Exane BNP Paribas initiates coverage on Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform rating and announces Price Target of $286.

Initiation

Exane BNP Paribas Initiates Coverage On Veeva Systems with Outperform Rating, Announces Price Target of $286

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.15% on an annualized basis producing an average annual return of 22.85%. Currently, Veeva Systems has a market capitalization of $32.68 billion. 
Buying $100 In VEEV: If an investor had bought $100 of VEEV stock 10 years ago, it would be worth $793.08 today based on a price of $203.12 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728329410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Veeva Systems Stock In The Last 10 Years

17 analysts have shared their evaluations of Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $236.24, a high estimate of $281.00, and a low estimate of $192.00. This upward trend is evident, with the current average reflecting a 4.67% increase from the previous average price target of $225.69.
<img src="https://www.benzinga.com/files/images/story/2024/1727816408_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Veeva Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Wallace</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$249.00</td>
<td>$233.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$208.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$207.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$192.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$281.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Jack Wallace</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$233.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$240.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veeva Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veeva Systems compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Veeva Systems's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Veeva Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VEEV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veeva Systems analyst ratings.</a>
<h2>Get to Know Veeva Systems Better</h2>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>Veeva Systems: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Veeva Systems's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of 14.56%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Veeva Systems's net margin excels beyond industry benchmarks, reaching 25.3%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Veeva Systems's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veeva Systems's ROA excels beyond industry benchmarks, reaching 2.73%. This signifies efficient management of assets and strong financial health.
Debt Management: Veeva Systems's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

17 Analysts Assess Veeva Systems: What You Need To Know

Guggenheim analyst Jack Wallace maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $233 to $249.

Guggenheim Maintains Buy on Veeva Systems, Raises Price Target to $249

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.81% on an annualized basis producing an average annual return of 23.18%. Currently, Veeva Systems has a market capitalization of $34.01 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $7,849.39 today based on a price of $210.00 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727793053_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $7,800 Today

Veeva Systems Announced The Expansion Of Veeva Vault QMS, Adding New Capabilities To Manage Medtech Field Actions And Product Recalls

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.74% on an annualized basis producing an average annual return of 22.21%. Currently, Veeva Systems has a market capitalization of $35.63 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $7,278.37 today based on a price of $220.03 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726068615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Veeva Systems 10 Years Ago Would Be Worth This Much Today

JP Morgan analyst Anne Samuel maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Neutral and raises the price target from $203 to $208.

JP Morgan Maintains Neutral on Veeva Systems, Raises Price Target to $208

Baird analyst Joe Vruwink lowered the firm's price target on Veeva (VEEV) to $245 from $251 and keeps an Outperform rating on the shares. The firm ...

Veeva price target lowered to $245 from $251 at Baird

Healthcare Investing Finding Growth Beyond Pharmaceuticals

CVS Health, Apollo Global Management, And Novo Nordisk Reported Results

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on Veeva Systems (VEEV – Research Report). The company's...

Veeva Systems (VEEV) Receives a Hold from Truist Financial

Virtual Investor Day to be held on November 7 at 4:30 pm.

Veeva to hold virtual investor day

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nkarta (NKTX – Research Report) and Veeva Systems (V...

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Veeva Systems (VEEV)

RBC Capital analyst Rishi Jaluria maintained a Buy rating on Veeva Systems (VEEV – Research Report) yesterday and set a price target of $275.00. Th...

RBC Capital Reaffirms Their Buy Rating on Veeva Systems (VEEV)

Oppenheimer analyst Kenneth Wong maintained a Buy rating on Veeva Systems (VEEV – Research Report) today and set a price target of $230.00. The com...

Veeva Systems (VEEV) Gets a Buy from Oppenheimer

RBC Capital raised the firm's price target on Veeva (VEEV) to $275 from $250 and keeps an Outperform rating on the shares. The company's investor d...

Veeva price target raised to $275 from $250 at RBC Capital

TD Cowen analyst Charles Rhyee maintained a Hold rating on Veeva Systems (VEEV – Research Report) today and set a price target of $244.00. Charles ...

Veeva Systems: Hold Rating Amid Uncertain Growth Projections and Market Challenges

AAPL

ABNB

AGNG

ANET

ARKG

BMED

CBLL

CNCR

CPRI

CTVA

EDOC

FANG

FHLC

FTXH

GEHC

GILD

GNOM

HART

HELX

HMST

HTEC

IBBQ

IDNA

IDXX

ILMN

ISRG

LABU

MCHP

MDEV

MELI

MSFT

NKTX

NXPI

PARA

PARAA

PILL

PINK

PLTR

PSCH

QCOM

QRVO

RACE

RDDT

RSPH

SAVE

SBIO

SKYQ

STFS

TTWO

UTHR

VRTX

WDNA

Press Releases

Life Sciences Community Advances Toward Next Phase of Innovation at Veeva R&D and Quality Summit

Veeva Vault LIMS Gains Momentum as Companies Unify Quality Assurance and Quality Control

New Service Center in Veeva Vault CRM Suite Unifies Sales and Service

Earnings

Veeva Announces Fiscal 2025 Second Quarter Results

Veeva to Present at Upcoming Investor Conference

Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors

Veeva Vault QMS Adds Field Actions and Recall Management for Medtech

18 of the Top 20 Medtech Companies Partner with Veeva MedTech to Get Devices and Diagnostics to Patients Faster

Comments

Veeva Systems

Veeva Systems (VEEV) Opciones

Veeva Systems (NYSE:VEEV) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL